Mindpeak wins EU IVDR certification for AI pathology software

Mindpeak said it has earned certification under the EU’s In Vitro Diagnostic Regulation after a review by BSI, a step that puts its quality system under Europe’s toughest diagnostic-device standard. The Hamburg AI pathology company says the milestone strengthens its ability to expand with labs and partners across Europe.

Why it matters: - The certification puts Mindpeak’s quality management system under the EU’s strictest standard for cancer-related diagnostic software. - IVDR compliance matters because it covers the full product lifecycle, including design, development, manufacturing, distribution and post-market surveillance. - The milestone can make it easier for Mindpeak to deepen partnerships with laboratories and diagnostic groups across Europe.

What happened: - Mindpeak announced it has achieved certification under the EU In Vitro Diagnostic Medical Devices Regulation. - BSI, a European Notified Body, issued the certification after a regulatory assessment. - The company is based in Hamburg, Germany. - CEO and Founder Felix Faber called the certification a defining milestone and said it shows the technology meets the standard that governs diagnostic devices used in patient care across Europe.

The details: - Mindpeak’s certified quality management system meets ISO 13485 and IVDR Annex IX requirements. - BSI Group confirmed that the system meets those standards. - IVDR requires manufacturers to show robust, auditable quality processes across the full device lifecycle. - The certification places Mindpeak’s organizational infrastructure on the same regulatory footing required for IVD devices on the EU market. - Mindpeak builds AI-powered software for digital pathology. - The company says its tools support biomarker development, clinical diagnostics, routine diagnostics and translation of novel biomarkers into clinical use. - Mindpeak’s technology analyzes IHC, H&E and mIF tissue images. - The software is used for subcellular biomarker quantification and predictive patient stratification.

Between the lines: - The certification is more than a paperwork milestone. It signals that Mindpeak has built regulatory processes mature enough for clinical-use software in a tightly regulated market. - For AI diagnostics companies, EU IVDR status can be a competitive differentiator because buyers in pathology and laboratory medicine often need strong compliance signals before adoption. - The announcement suggests Mindpeak is positioning itself for broader commercial scale in Europe, not just technical validation.

What's next: - Mindpeak is expected to use the certification to support further expansion with laboratory and diagnostic partners across Europe. - The company says the certification will help form the foundation for the next phase of its platform. - Mindpeak will continue developing AI-powered pathology tools for high-stakes clinical decision-making.

The bottom line: - Mindpeak now has a key EU regulatory credential that can help it compete in clinical AI pathology, where trust and compliance are as important as model performance. - More information is available on Mindpeak’s website and LinkedIn.